Physician profile
Scott F Avery
NPI 1427230069
$195,086.46
in general payments reported to CMS, 2019-2025
10 companies · $121K in 2025
The $121K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $205 · 2021: $300 · 2022: $295 · 2023: $348 · 2024: $73K · 2025: $121K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $165K · Travel and Lodging: $20K · Food and Beverage: $7,841 · Consulting Fee: $395 · Education: $353.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $165,340.60 |
| Travel and Lodging | $20,357.12 |
| Food and Beverage | $7,841.11 |
| Consulting Fee | $395.00 |
| Education | $353.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $170,862.25 | 2023-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Otsuka America Pharmaceutical, INC. | $21,887.42 | 2022-2025 | Rexulti, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $1,148.63 | 2019-2025 | Ingrezza |
| Acadia Pharmaceuticals INC | $470.02 | 2024-2025 | Nuplazid |
| Axsome Therapeutics, INC. | $242.60 | 2024-2025 | Auvelity |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $197.70 | 2024-2025 | Rexulti |
| Smith+Nephew, INC. | $119.41 | 2022 | |
| Janssen Pharmaceuticals, INC | $109.50 | 2019 | |
| Sk Life Science, INC. | $31.24 | 2025 | |
| Lundbeck LLC | $17.69 | 2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Avery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.